{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-093782","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-08-11T12:10:25+00:00","discovered_at":"2026-08-11T12:15:32.479308+00:00","generated_at":"2026-08-11T12:15:38.785669+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Theriva Biologics Q2 2026: Cash $11.3M, VIRAGE2 first patients dosed","bullets":["Cash and cash equivalents $11.3M as of June 30, 2026; runway into Q1 2027.","G&A expenses down 82% YoY to $2.0M from $11.2M; prior-year $9.2M contingent consideration adjustment.","R&D expenses down 35% to $1.3M from $2.0M; H1 2026 net loss $5.3M.","First patients dosed in VIRAGE2 Phase 2a trial of VCN-01 in metastatic PDAC; enrollment completion expected H2 2026.","Proposed Phase 2/3 retinoblastoma trial design completed; FDA discussion planned Q3 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-093782","json":"https://secwatch.observer/filing/0001104659-26-093782.json","markdown":"https://secwatch.observer/filing/0001104659-26-093782.md","text":"https://secwatch.observer/filing/0001104659-26-093782.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/0001104659-26-093782-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926093782/tm2622636d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:15:38.785669+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}